|
| Sample type | Sample entity (cases) | Purpose of study | Method | Literature | Study contents |
|
| | Osteosarcoma (16) | Chemosensitivity | 2D-DIGE | Kawai et al. |
Chemosensitivity (poor responder (7) versus good responder (9)) |
| Patient's tissue samples (osteosarcoma, normal bone, and benign tumor) | Osteosarcoma (5) and normal bone (5) | Tumor-specific and malignancy | 2D-DIGE | Folio et al. | Tumor-specific proteins (osteosarcoma (5) versus normal bone (5)) |
| Osteosarcoma (12) | Chemosensitivity | 2D-DIGE | Kikuta et al. | Chemosensitivity (poor responder (6) versus good responder (6)) |
| | Osteosarcoma (5), chondroblastoma (2), osteoblastoma (2), and giant cell tumor (1) | Tumor-specific and malignancy | 2DE | Li et al. | Tumor-specific proteins (osteosarcoma (5) versus chondroblastoma (2), osteoblastoma (2), and giant cell tumor (1)) |
|
| Patient's plasma samples (osteosarcoma and benign tumor) | Osteosarcoma (29) and osteoblastoma (20) | Tumor-specific and malignancy | SELDI | Li et al. |
Tumor-specific proteins (osteosarcoma (29) versus osteoblastoma (20)) |
| Osteosarcoma (54) | Chemosensitivity | SELDI | Li et al. | Tumor-specific proteins (poor responder (27) versus good responder (27)) |
|
| | Osteosarcoma cell (1), osteoblastic cell (1) | Tumor-specific and malignancy | 2DE | Spreafico et al. |
Tumor-specific proteins (SaOS-2 (1) versus osteoblastic cell (1)) |
| Cell line samples (osteosarcoma cell line versus normal bone or osteoblast cell) | Osteosarcoma cell (3), osteoblastic cell (1) | Tumor-specific and malignancy | 2DE | Guo et al. | Tumor-specific proteins (U2OS (1), IOR/OS9 (1) and SaOS-2 (1) versus osteoblastic cell (1)) |
| Osteosarcoma cell (1), osteoblastic cell (1) | Tumor-specific and malignancy | 2DE | Liu et al. | Tumor-specific proteins (SaOS-2 (1) versus osteoblastic cell (1)) |
| Osteosarcoma cell (1), osteoblastic cell (1) | Tumor-specific and malignancy | iTRAQ | Zhang et al. | Tumor-specific proteins of plasma membrane (MG63 (1) versus osteoblastic cell (1)) |
| | Osteosarcoma cell (1), osteoblastic cell (1) | Tumor-specific and malignancy | 2D-DIGE | Hua et al. | Tumor-specific proteins of plasma membrane (MG63 (1) versus osteoblastic cell (1)) |
|
|
Cell line sample (osetosarcoma cell) | Osteosarcoma cell (1) | Tumor specific | 2D-DIGE | Niforou et al. | Characteristic proteins of U2OS cell line |
|
|
Cell line sample (high metastatic osetosarcoma cell versus low metastatic osteosarcoma cell) | Osteosarcoma cell (2) | Metastasis | MALDI and 2D-DIGE | Cates et al. | Proteins corresponding to metastasis (high metastatic osetosarcoma cell (1) versus low metastatic osetosarcoma cell (2)) |
|
| | Osteosarcoma cell (2) | Drug-sensitivity | 2DE | Kang et al. |
Drug-sensitivity: Ascochlorin (drug-treatment U2OS (1) versus no-treatment U2OS (1)) |
| Cell line sample (drug treatment cell versus nontreatment cell) | Osteosarcoma cell (2) | Drug-sensitivity | 2DE | Chang et al. | Drug-sensitivity: Ascochlorin (drug-treatment USOS (1) versus no-treatment USOS (1)) |
| | Osteosarcoma cell (2) | Drug-sensitivity | 2DE | Zhang et al. | Drug-sensitivity: DATS (drug-treatment SaOS2 (1) versus non-treatment SaOS2 (1)) |
|
| Cell line sample (target inhibition or activation cell versus non-treatment cell) | Osteosarcoma cell (2) | Target related proteins | 2D-DIGE | Li et al. |
Target-related proteins: E2F1 (E2F1-activated SaOS2 (1) versus non-treatment SaOS2 (1)) |
| Osteosarcoma cell (4) | Target related proteins | 2D-DIGE | Annunen-
Rasia et al. | Target-related proteins: (i) OXPHOS, (ii) CI or CV, and (iii) mtDNA (inhibited SaOS2 (1) versus non-treatment SaOS2 (1)) |
|
